• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA approves AbbVie’s Orilissa for endometriosis pain pharmaceutical-technology
    July 26, 2018
    The US Food and Drug Administration (FDA) has approved AbbVie and Neurocrine Biosciences’ drug Orilissa (elagolix) for women with moderate to severe endometriosis pain.
  • US approves AbbVie/Neurocrine’s uterine pain drug pharmatimes
    July 26, 2018
    AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
Previous page 1 2 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service